IL-17 Switching Works in Psoriatic Disease Save
Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.
The IL-17 cytokine family encompasses six different homodimers and heterodimers referred to as IL-17A–F and there are 3 currently marketed IL-17 inhibitors (secukinumab, ixekizumab, brodalumab). While SEC and IXE target IL-17A and BRO targets IL-17A/F, the success of switching between theses different IL-17 inhibitors is not well studied.
This registry included 90 patients with psoriatic arthritis and psoriasis patients with severe chronic plaque psoriasis and baseline PASI scores >10 both prior to first-line biological therapy initiation and after switch to another agent of the class of IL-17 inhibitors.
Most effective switch was from SEC to BRO, achieving PASI 90 of 64.7% at week 12 and 73.3% at week 24.
Those switching from SEC to IXE, the PASI 90 responses were 41% at weeks 1 and 55.2% by week 24.
Switching from IXE to BRO resulted in a PASI 90 in 30.8% and 38.5% of patients by week 12 and 24, respectively.
Therapeutic responses and treatment success of IL-17 switches were independent of the patient's body weight and presence of psoriatic arthritis.
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.